Tempest Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 17
- Market Cap
- $33.7M
- Website
- http://www.tempesttx.com
- Introduction
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Phase 3
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Tempest Therapeutics
- Target Recruit Count
- 740
- Registration Number
- NCT06680258
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Endometrial CancerGastric AdenocarcinomaSolid TumorColorectal CancerSquamous Cell Carcinoma of Head and NeckNon Small Cell Lung CancerUrothelial CarcinomaSolid Tumors With PIK3Ca MutationGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: TPST-1495 once daily or on intermittent scheduleDrug: TPST-1495 twice daily
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Tempest Therapeutics
- Target Recruit Count
- 175
- Registration Number
- NCT04344795
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Baystate Gynecologic Oncology, Springfield, Massachusetts, United States
🇺🇸University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1
Completed
- Conditions
- Metastatic Castration Resistant Prostate CancerNon-small Cell Lung CancerTriple-Negative Breast CancerPancreatic CancerColorectal CancerSquamous Cell Carcinoma of Head and NeckCholangiocarcinomaHepatocellular CarcinomaUrothelial CarcinomaGastroEsophageal Cancer
- Interventions
- Drug: Part 1 TPST-1120Drug: Part 2 TPST-1120 + nivolumabDrug: Part 3 TPST-1120Drug: Part 4 TPST-1120 + nivolumab
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Tempest Therapeutics
- Target Recruit Count
- 38
- Registration Number
- NCT03829436
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath